scholarly journals Comparative analysis of long-term treatment outcomes in patients with locally advanced prostate cancer

2021 ◽  
Vol 20 (2) ◽  
pp. 23-27
Author(s):  
G. V. Galina ◽  
Р. A. Karnaukh ◽  
D. M. Timokhina ◽  
E. A. Kyprianov
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Survival Rate ◽  
Hormone Therapy ◽  
Survival Rates ◽  
Pelvic Lymphadenectomy ◽  
Adjuvant Hormone Therapy ◽  
One Year ◽  
The One ◽  
Group 1

Introduction. The aim of the study was to compare the survival rates of patients with prostate cancer (PC) with lymphogenic metastases (N1) after surgical treatment and after conformal distant radiation therapy followed by adjuvant hormone therapy with analogues of luteinizing-releasing hormone (LHRH).Materials and methods. The patients were divided into two groups. The first group included 36 patients with prostate cancer after posadilonic prostatectomy with extended pelvic lymphadenectomy followed by continuous adjuvant hormone therapy (analogs of LGRH) for up to two to three years. Lymphogenic metastases were detected after histological examination of the operative material. The second group consisted of 42 patients after neoadjuvant hormone therapy for 6 months (LGRH analogues), a course of distant radiation therapy (DLT) in the traditional mode with a single focal dose (ROD) of 2 Gray (Gy), a total focal dose (SOD) of 72 Gy, followed by adjuvant hormone therapy in a continuous mode (analogs of LGRH) for up to two to three years.Results. The duration of follow-up was 60 months, with a median of 38 months. The one-year survival rate after surgery was 86.1%, in the group after DLT — 81.2%, the three-year survival rate in group 1 — 80.1%, in group 2 — 76.3%, the five-year survival rates — 72.3% and 69.1% respectively. The one-year cancer-specific survival rate in group 1 was 96.7%, the three-year survival rate was 83.4%, and the five-year survival rate was 52.8%. In the second group, the oneyear survival rate was 91.9%, the three-year survival rate was 74.1%, and the five-year survival rate was 51.4%. Conclusion. For the treatment of prostate cancer patients with lymphogenic metastases, prostatectomy with extended pelvic lymphadenectomy can be considered as a treatment option not only in clinical trials. The results of cancer-specific and relapse-free survival show the effectiveness of this treatment option

scholarly journals Comparative Efficiency of Removable Mini-Implant Retained Dentures Using Different Attachments in Edentulous Patients

2019 ◽  
Vol 26 (5) ◽  
pp. 52-64
Author(s):  
Stanislav Yu. Maksyukov ◽  
Viktoria A. Prokhodnaya ◽  
Konstantin D. Pilipenko ◽  
Natalya V. Lapina ◽  
Viktor L. Popkov ◽  
...  
Keyword(s):  
Survival Rate ◽  
Negative Part ◽  
Comparative Efficiency ◽  
Implant Placement ◽  
Group 3 ◽  
Group 2 ◽  
Edentulous Patients ◽  
One Year ◽  
The One ◽  
Group 1

Aim. To compare the efficiency of removable mini-implant retained dentures using different types of attachment.Materials and methods. The study included 51 edentulous patients. The patients were divided into three groups according to the attachment type and abutment shape: 1) ball-and-socket attachment, ball abutment (n = 26); 2) locator attachment, equator abutment, XiVE LOCATOR system (n = 14); 3) bar attachment (n = 11). Removable dentures were made of ordinary acrylic plastic. The placement of intraosseous dental implants with their sublingual engraftment was performed according to the traditional two-stage delayed-load procedure. The efficiency of implants was evaluated using the method of M.Z. Mirgazizov and the eponymous index. The dynamics of vertical bone resorption around implants was determined using dental panoramic radiography (6 months, 1 and 2 years after the treatment). A periotest was performed 6 months after the end of the orthopaedic treatment.Results. The one-year survival rate of implants reached 96.2% in group 1, amounting to 100% in groups 2 and 3. The two-year survival rate came to 92.3% in group 1, reaching 92.9% and 100% in groups 2 and 3, respectively. Inflammatory phenomena characteristic of peri-implantitis were noted one year after the implant placement in 7.7% (n = 2) of patients in group 1 and in 7.1% of patients in group 2, with no inflammatory phenomena being observed in group 3. Two years after the implant placement, peri-implantitis was observed in 19.2% and 21.4% of patients in groups 1 and 2, respectively, coming to 9.1% in group 3. The periotest revealed that six months after the placement, implant stability was higher in group 3 for both the lower and upper jaw (in comparison with groups 1 and 2), as evidenced by the shift in periotest values towards the negative part of the scale.Conclusion. The study revealed that bar attachment, as well as locator attachment (equator abutments), of removable dentures supported by mini implants is more efficient as compared to the ball-and-socket attachment.

Overall survival outcomes with the use of adjuvant chemotherapy, radiation therapy and hormone therapy in high-risk, very-high-risk and node-positive prostate cancer post radical prostatectomy: A NCDB analysis.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 118-118
Author(s):  
Alina Basnet ◽  
Margaret K Formica ◽  
Poornima Ramadas ◽  
Sam Benjamin
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Radical Prostatectomy ◽  
Hormone Therapy ◽  
Group 2 ◽  
Very High ◽  
Group 1

118 Background: Phase III trials have not consistently demonstrated overall survival (OS) advantage of adjuvant radiation therapy (ART) in prostate cancer (PC) with high risk/very high risk features after radical prostatectomy (RP). Adjuvant hormone therapy (AHT) in PC after RP improved OS in patients with positive lymph nodes (pLNs). We report an observational study on the impact of AHT to ART in NCCN defined high-risk/very high risk (Group 1), and adjuvant chemotherapy (ACT) to AHT in pLNs (group 2) post RP on OS. Methods: We conducted a retrospective study of PC patients (group 1 and group 2) who underwent RP and/or pelvic lymph node dissection. OS was calculated using Kaplan Meier analysis. Group 1 compared ART+AHT vs ART and Group 2 AHT+ ACT vs AHT within 16 weeks of RP. Multivariate analysis was performed with Cox proportional hazard regression model to adjust for different variables. Results: Out of 1,390,357 PC patients reported in NCDB (2004-2015) 182,653 and 11,972 met our inclusion criteria for Group 1 and Group 2 respectively. 3.37% of Group 1 received ART and/or AHT. 19.81% of Group 2 received AHT and/or ACT. Patients who received ART + AHT were more likely to be older, Non-Hispanic white, more likely to have pT4, and have higher prostate specific antigen (PSA) and Gleason scores (GS). Patients who received AHT+ACT were more likely to be younger, with private insurance, and lower Charlson-Deyo Score (CDCC) score. Five and seven year OS with adjusted hazard ratio (aHR) among Group 1 and Group 2 are depicted in table. Conclusions: No statistically significant difference in OS was seen among respective treatment groups. Limitations that exist with this registry based study include lack of randomization, differences in surgical and radiation techniques, duration and choices of ACT and AHT.[Table: see text]

Canine mandibular osteosarcoma: 51 cases (1980-1992)

1996 ◽  
Vol 32 (3) ◽  
pp. 257-262 ◽  
Author(s):  
RC Straw ◽  
BE Powers ◽  
J Klausner ◽  
RA Henderson ◽  
WB Morrison ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Survival Rate ◽  
Histological Grade ◽  
Survival Outcome ◽  
Hazard Ratio ◽  
Treatment Modalities ◽  
Apparent Effect ◽  
Histological Score ◽  
One Year ◽  
The One

Fifty-one dogs treated for mandibular osteosarcomas (OSs) were studied retrospectively. Treatments were partial mandibulectomy (n = 32); partial mandibulectomy and chemotherapy (n = 10); partial mandibulectomy and radiation therapy (n = 3); partial mandibulectomy, radiation therapy, and chemotherapy (n = 4); and radiation therapy alone (n = 2). The overall one-year survival rate was 59.3%. Dogs treated with surgery alone had a one-year survival rate of 71%, which is higher than the one-year survival rate for dogs with appendicular OSs treated with surgery alone (p of 0.001 or less; hazard ratio of 0.29). There was no apparent effect of various treatment modalities, nor institution where treatment was given, nor histological type. Histological score and, to a lesser extent, histological grade were predictive of survival outcome.

scholarly journals Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

2021 ◽  
Vol 10 (2) ◽  
pp. 294
Author(s):  
Atsushi Hosui ◽  
Takafumi Tanimoto ◽  
Toru Okahara ◽  
Munehiro Ashida ◽  
Kohsaku Ohnishi ◽  
...  
Keyword(s):  
Conventional Therapy ◽  
Low Dose ◽  
Therapy Group ◽  
Survival Rates ◽  
Refractory Ascites ◽  
High Dose ◽  
Term Survival ◽  
Conventional Therapy Group ◽  
One Year ◽  
The One

(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites. (2) Patients and methods: A total of 206 patients who responded insufficiently to conventional diuretics and were hospitalized for refractory ascites for the first time were retrospectively enrolled in this study. Among them, the first 57 consecutive patients were treated with conventional diuretics (the conventional therapy group); the latter 149 consecutive patients were treated with tolvaptan in addition to the conventional therapy (the tolvaptan group). (3) Results: The exacerbation of renal function was significantly milder in the tolvaptan group than in the conventional therapy group. The prognostic factors for survival in the tolvaptan group were being male, having hyperbilirubinemia, having a high blood urea nitrogen (BUN), and receiving high-dose furosemide at the start of tolvaptan treatment. The one-year and three-year cumulative survival rates were 67.8 and 45.3%, respectively, in patients with low-dose furosemide (<40 mg/day) at the start of tolvaptan treatment. The prognosis was significantly better in the tolvaptan group with low-dose furosemide than in the conventional therapy group (p < 0.001). (4) Conclusion: Tolvaptan can improve survival in patients with cirrhotic ascites, especially when tolvaptan is started before high-dose furosemide administration.

Prostate Cancer: Population-Based Survival Rates in Central Italy

1995 ◽  
Vol 81 (2) ◽  
pp. 81-85 ◽  
Author(s):  
Emanuele Crocetti ◽  
Eva Buiatti ◽  
Andrea Amorosi
Keyword(s):  
Prostate Cancer ◽  
Central Italy ◽  
Survival Rates ◽  
Relative Survival ◽  
Tumor Grade ◽  
Population Based ◽  
Prognostic Effect ◽  
Disease Extension ◽  
The One ◽  
Histological Verification

Aims To evaluate survival in prostate cancer patients in the Province of Florence where the Tuscany Cancer Registry is active. Methods The survival of 777 patients with prostate cancer diagnosed in the period 1985-87 was evaluated. The observed and relative survival rates 1, 3 and 5 years after diagnosis were computed. Also the prognostic effect of age, disease extension, tumor grade, histological verification, place of residence and year of diagnosis were evaluated using univariate and multivariate analysis. Results The observed survival was 73.4% 1 year, 42.5% 3 years and 29.2% 5 years after diagnosis. The relative survival was respectively 78.7%, 53.0% and 43.0%. Significant independent risks were evident when the disease was extended out of the prostate, for patients older than 80 years, for high grade tumors and for patients without histological verification. Conclusion The 5-year relative survival rate in the province of Florence is similar to those from other European Registries and the Latina Registry, but much lower than the one reported by the SEER program in the US. Data on histological verification percentage, availability of information on disease extension, and tumor grade are discussed as indicators of the quality of the diagnostic approach in comparison with other registries.

A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer

2018 ◽  
Vol 73 (2) ◽  
pp. 156-165 ◽  
Author(s):  
Daniel E. Spratt ◽  
Robert T. Dess ◽  
Zachary S. Zumsteg ◽  
Daniel W. Lin ◽  
Phuoc T. Tran ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
Hormone Therapy ◽  
Recurrent Prostate Cancer ◽  
Salvage Radiation Therapy

scholarly journals Pulsed Radiofrequency for Chronic Inguinal Neuralgia

2015 ◽  
Vol 2;18 (2;3) ◽  
pp. E147-E155
Author(s):  
Yasser M. Amr
Keyword(s):  
Pain Relief ◽  
Nerve Root ◽  
Small Sample ◽  
Pulsed Radiofrequency ◽  
Group 2 ◽  
One Year ◽  
The One ◽  
Inguinal Neuralgia ◽  
Group 1

Background: Chronic inguinal neuralgia has been reported after inguinal herniorrhaphy, caesarean section, appendectomy, and trauma to the lower quadrant of the abdomen or inguinal region. Objectives: This study was designed to evaluate the efficacy of pulsed radiofrequency in management of chronic inguinal neuralgia. Study Design: Randomized, double-blind controlled trial. Setting: Hospital outpatient setting. Methods: Twenty-one patients were allocated into 2 groups. Group 1 received 2 cycles of pulsed radiofrequency (PRF) for each nerve root. In Group 2, after stimulation, we spent the same time to mimic PRF. Both groups received bupivacaine 0.25% + 4 mg dexamethasone in 2 mL for each nerve root. Visual Analogue Scale (VAS) was assessed. Duration of the first block effective pain relief was reported. Repeated PRF blockade was allowed for any patient who reported a VAS > 30 mm in both groups during the one year follow-up period. The number and duration of blocks were reported and adverse effects were also reported. Results: Significantly longer duration of pain relief was noticed in Group 1 (P = 0.005) after the first block, while the durations of pain relief of the second block were comparable (P = 0.59). In Group 1 the second PRF produced pain relief from the twenty-fourth week until the tenth month while in Group 2, pain relief was reported from the sixteenth week until the eighth month after the use of PRF. All patients in Group 2 received 3 blocks (the first was a sham PRF) during the one year follow-up period. Meanwhile, 2 PRF blocks were sufficient to achieve pain relief for patients in Group 1 except 4 patients who needed a third PRF block. No adverse events were reported. Limitations: Small sample size. Conclusion: For intractable chronic inguinal pain, PRF for the dorsal root ganglion represents a promising treatment modality. Key words: Radiofrequency, chronic, inguinal neuralgia

Sign in / Sign up

Export Citation Format

Share Document